Summary
266.51 -0.60(-0.22%)05/21/2024
Danaher Corp. (DHR)
Danaher Corp. (DHR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.53 | 0.85 | 1.89 | 0.84 | 25.46 | 17.56 | 118.98 | 360,295.87 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 248.72 | |
| Open | 246.54 | |
| High | 249.10 | |
| Low | 246.20 | |
| Volume | 1,136,869 | |
| Change | 1.32 | |
| Change % | 0.53 | |
| Avg Volume (20 Days) | 2,434,657 | |
| Volume/Avg Volume (20 Days) Ratio | 0.47 | |
| 52 Week Range | 182.09 - 259.00 | |
| Price vs 52 Week High | -3.97% | |
| Price vs 52 Week Low | 36.59% | |
| Range | 0.88 | |
| Gap Up/Down | -2.91 | |
Fundamentals | ||
| Market Capitalization (Mln) | 197,845 | |
| EBIDTA | 7,416,999,936 | |
| PE Ratio | 46.4917 | |
| PEG Ratio | 3.1267 | |
| WallStreet Target Price | 271.39 | |
| Book Value | 72.1600 | |
| Earnings Per Share | 5.4500 | |
| EPS Estimate Current Quarter | 1.6000 | |
| EPS Estimate Next Quarter | 1.5700 | |
| EPS Estimate Current Year | 7.6100 | |
| EPS Estimate Next Year | 8.6700 | |
| Diluted EPS (TTM) | 5.4500 | |
| Revenues | ||
| Profit Marging | 0.1855 | |
| Operating Marging (TTM) | 0.2309 | |
| Return on asset (TTM) | 0.0386 | |
| Return on equity (TTM) | 0.0776 | |
| Revenue TTM | 23,736,999,936 | |
| Revenue per share TTM | 32.1070 | |
| Quarterly Revenue Growth (YOY) | -0.0260 | |
| Quarterly Earnings Growth (YOY) | -0.2510 | |
| Gross Profit (TTM) | 18,949,000,000 | |
| Dividends | ||
| Dividend Share | 1.0500 | |
| Dividend Yield | 0.0043 | |
| Valuations | ||
| Trailing PE | 46.4917 | |
| Forward PE | 31.4465 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.3222 | |
| Revenue Enterprise Value | 8.0103 | |
| EBITDA Enterprise Value | 25.5290 | |
| Shares | ||
| Shares Outstanding | 740,686,976 | |
| Shares Float | 660,144,287 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 10.75 | |
| Institutions (%) | 82.09 | |
05/15 11:46 EST - zacks.com
Danaher (DHR) Rides on Business Strength Amid Headwinds
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
Danaher (DHR) Rides on Business Strength Amid Headwinds
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
05/14 17:00 EST - seekingalpha.com
Danaher Corporation (DHR) Presents at BofA Securities 2024 Health Care Conference Call Transcript
Sirius XM Holdings Inc. (SIRI) BofA Securities 2024 Health Care Conference Call May 14, 2024 1:40 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Michael Ryskin - Bank of America Michael Ryskin Everyone will kick things off for our next session. My name is Mike Ryskin.
Danaher Corporation (DHR) Presents at BofA Securities 2024 Health Care Conference Call Transcript
Sirius XM Holdings Inc. (SIRI) BofA Securities 2024 Health Care Conference Call May 14, 2024 1:40 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Michael Ryskin - Bank of America Michael Ryskin Everyone will kick things off for our next session. My name is Mike Ryskin.
05/09 07:00 EST - prnewswire.com
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics.
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics.
05/08 10:02 EST - zacks.com
Danaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Danaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
05/07 16:45 EST - prnewswire.com
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Tuesday, May 14, 2024 at 10:40 a.m.
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Tuesday, May 14, 2024 at 10:40 a.m.
05/07 16:15 EST - prnewswire.com
Danaher Announces Quarterly Dividend
WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 26, 2024 to holders of record on June 28, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.
Danaher Announces Quarterly Dividend
WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 26, 2024 to holders of record on June 28, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.
05/03 09:06 EST - prnewswire.com
Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry
WOBURN, Mass. , May 3, 2024 /PRNewswire/ -- Curiox Biosystems Co. Ltd (Curiox), a leader in the innovation of life science research technologies, and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announce a strategic partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry.
Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry
WOBURN, Mass. , May 3, 2024 /PRNewswire/ -- Curiox Biosystems Co. Ltd (Curiox), a leader in the innovation of life science research technologies, and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announce a strategic partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry.
05/01 09:15 EST - forbes.com
The Forgotten Stock Advice That Delivers 170%+ Payout Growth
One of the best ways to grab a dividend payer set to surge is a strategy you never hear about anymore: Pick up shares of a conglomerate.
The Forgotten Stock Advice That Delivers 170%+ Payout Growth
One of the best ways to grab a dividend payer set to surge is a strategy you never hear about anymore: Pick up shares of a conglomerate.
04/26 08:00 EST - forbes.com
What Should You Do With Danaher Stock At $250 After Q1 Beat?
Danaher stock (NYSE: DHR), a conglomerate with products in life sciences, biotechnology, and diagnostics fields, recently posted its Q1 results that exceeded the street expectations. The company reported revenue of $5.8 billion and adjusted earnings of $1.92 per share, compared to the consensus estimates of $5.3 billion and $1.60, respectively.
What Should You Do With Danaher Stock At $250 After Q1 Beat?
Danaher stock (NYSE: DHR), a conglomerate with products in life sciences, biotechnology, and diagnostics fields, recently posted its Q1 results that exceeded the street expectations. The company reported revenue of $5.8 billion and adjusted earnings of $1.92 per share, compared to the consensus estimates of $5.3 billion and $1.60, respectively.
04/23 12:31 EST - zacks.com
Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y
While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.
Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y
While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.
04/23 11:33 EST - investors.com
Earnings Today: PulteGroup, Danaher Rally; JetBlue Dives
PulteGroup received an added data boost, Danaher's markets are looking up, and JetBlue collapses, despite a not-as-bad-as-feared loss.
Earnings Today: PulteGroup, Danaher Rally; JetBlue Dives
PulteGroup received an added data boost, Danaher's markets are looking up, and JetBlue collapses, despite a not-as-bad-as-feared loss.
04/23 10:36 EST - zacks.com
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
04/23 08:13 EST - barrons.com
Danaher Shrugs Off Outlook for Falling Sales
The medical company reported first-quarter adjusted earnings of $1.92 a share, beating Wall Street's call for $1.72.
Danaher Shrugs Off Outlook for Falling Sales
The medical company reported first-quarter adjusted earnings of $1.92 a share, beating Wall Street's call for $1.72.
04/23 08:11 EST - zacks.com
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
Danaher (DHR) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.72 per share. This compares to earnings of $2.36 per share a year ago.
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
Danaher (DHR) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.72 per share. This compares to earnings of $2.36 per share a year ago.
04/23 07:04 EST - reuters.com
Danaher beats quarterly estimates on strength in diagnostics business
Danaher beat quarterly profit and sales expectations on Tuesday, driven by strength in its diagnostics and bioprocessing businesses, sending shares of the life sciences firm up more than 7% before the bell.
Danaher beats quarterly estimates on strength in diagnostics business
Danaher beat quarterly profit and sales expectations on Tuesday, driven by strength in its diagnostics and bioprocessing businesses, sending shares of the life sciences firm up more than 7% before the bell.
04/23 06:00 EST - prnewswire.com
Danaher Reports First Quarter 2024 Results
WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted.
Danaher Reports First Quarter 2024 Results
WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted.
04/19 10:56 EST - zacks.com
Why Danaher (DHR) Might Surprise This Earnings Season
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Danaher (DHR) Might Surprise This Earnings Season
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
04/18 13:16 EST - zacks.com
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
04/18 12:01 EST - zacks.com
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
04/18 10:21 EST - zacks.com
Curious about Danaher (DHR) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Danaher (DHR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Curious about Danaher (DHR) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Danaher (DHR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.